Improving delivery of mRNA to stem and progenitor cells for better health.
Official title: Clinically-useful vehicles for in vivo delivery of mRNA to stem and progenitor cells
Funded at Rejuvenation Technologies, INC. · NIH-10830538 · Data updated 2026-11-12
This study is exploring a new way to deliver a special type of mRNA to help your body's cells heal and regenerate better, which could be really helpful for people dealing with age-related health issues or organ problems.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rejuvenation Technologies, INC. NIH-funded |
| Lab location | 1 site (Mountain View, UNITED STATES) |
| Project start | September 15, 2024 |
| Project end | September 14, 2025 |
| Funding year | 2024 |
| Award (this year) | $324,998 |
| NIH project number | 1R43GM153144-01 |
| Project ID | NIH-10830538 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would include individuals experiencing age-related decline in cell function or those with conditions related to cellular senescence.
✕Less likely to help
Patients with acute, non-age-related conditions or those who do not have issues related to progenitor cell function may not benefit from this research.
What this research studies
This research focuses on enhancing the delivery of telomerase mRNA to progenitor cells using a novel lipid nanoparticle (LNP) vehicle. By targeting these cells, the aim is to extend their regenerative capacity and improve overall cell health, which is crucial for combating age-related diseases and organ failure. The approach involves using a breakthrough LNP formulation that has shown the ability to transfect a wide range of tissues in non-human primates, indicating its potential effectiveness in humans. Patients may benefit from advancements in regenerative medicine that could arise from this innovative delivery method.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that enhance cell regeneration and improve healthspan for patients with age-related conditions.
How similar studies have gone: Other research has shown promise in using lipid nanoparticles for mRNA delivery, suggesting that this approach could be effective, though the specific targeting of progenitor cells is a novel aspect.
Where this research is happening
-
Rejuvenation Technologies, INC.
Mountain View, United States Active
Researchers
- Principal investigator: Ramunas, John — Rejuvenation Technologies, INC.
- Study coordinator: Ramunas, John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.